News and Trends 16 Nov 2017 German Diagnostics Firm Tackles Early Detection of Cancer, Alzheimer’s and Parkinson’s …(COPD), Alzheimer’s and Parkinson’s. Liquid biopsies, or diagnostic test based on blood samples, are a rapidly growing field. The technology has the potential to replace current diagnosis practices that are… November 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 23 Sep 2019 AC Immune Gets €28M from Eli Lilly as Alzheimer’s Drug Hits Phase I AC Immune will receive €27.6M (CHF 30M) from big pharma Eli Lilly as it begins a phase I trial of its first-in-class Alzheimer’s disease drug. This is the first milestone… September 23, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 9 Nov 2023 Blood tests for Alzheimer’s: a hit or a miss? …blood tests for Alzheimer’s is not fully understood, Trinh pointed out that these markers provide information on the presence of Alzheimer’s-related brain changes. The perks of these markers are three-fold,… November 9, 2023 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
More News! 17 Jul 2024 Is tau protein the key to defeating Alzheimer’s? Asceneuron thinks so and raises $100 million to prove it …candidate targeting tau proteins associated with Alzheimer’s disease. Asceneuron’s approach to tackling Alzheimer’s disease sets it apart in the competitive landscape of neurodegenerative disease treatments. While approved therapies for Alzheimer’s,… July 17, 2024 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Sponsored by WuXi AppTec 22 Sep 2021 Discovering New Therapeutic Targets for Alzheimer’s Disease …no dementia symptoms. Therefore, some researchers believe we need to investigate causative mechanisms more widely to develop alternative ways to treat Alzheimer’s disease. For example, Alzheimer’s is known to cause… September 22, 2021 - 7 minutesmins - By Julia Kaiser Share WhatsApp Twitter Linkedin Email
Best in Biotech 25 Nov 2025 11 neuroscience biotech companies you should know about …Announced that all 84 sites for its phase 3 study of buntanetap in early Alzheimer’s disease are now fully activated Focused on developing therapies for neurodegenerative disorders such as Alzheimer’s… November 25, 2025 - 16 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Interview 23 Nov 2022 What recent mixed clinical results can teach about Alzheimer’s disease …to slow Alzheimer’s disease. “It has not been proven yet whether this really translates into patient benefit.” The field faces mixed clinical results After disappointing clinical outcomes in the Alzheimer’s… November 23, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2023 Positive study results: Lilly’s Alzheimer’s drug slows patients’ decline …71% achieved clearance at 12 months). “Clinical benefit” for Alzheimer’s patients “Amyloid plaque is a defining pathophysiological feature of Alzheimer’s disease,” said Eric Reiman, CEO of Banner Research, one of… May 3, 2023 - 8 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 30 Nov 2023 Could an Alzheimer’s vaccine make treatment more affordable? …the brain that are associated with Alzheimer’s, vaccine trials are underway to eliminate these proteins. But how far along are these vaccines in the clinic? One of the awaited Alzheimer’s… November 30, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2020 Late-Stage Success Raises Hopes to Tackle Alzheimer’s via Inflammation …embodies a new wave of medical thinking about Alzheimer’s disease and neurodegenerative disorders in general. For years, the focus of Alzheimer’s research had been on the buildup of misfolded proteins… December 21, 2020 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
Startup Scout 16 Aug 2019 This Biotech Fights Alzheimer’s Disease by Targeting Support Brain Cells …the brain called astrocytes. Mission: To develop small molecule drugs targeting astrocytes, whose inflammatory activity is linked to the development of Alzheimer’s disease. Alzheimer’s disease is a highly debilitating neurodegenerative… August 16, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Dec 2025 Vandria reports VNA-318’s first-in-human data in Alzheimer’s …make an explicit push toward Alzheimer’s as a target. Indeed, beyond Vandria, most mitophagy work in Alzheimer’s remains academic, supported by a growing body of research linking impaired mitochondrial quality… December 2, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email